Using quantitative receptor autoradiography, [3HJD-Ala-t~-Leu-enkephalin (DADL) and [~H]naloxonc binding were studicd in rat striatum and striatal projection areas (globus pallidus (GP) and substantia nigra pars reticulata (SN~)) after unilateral striatal kainic acid lesions, pH]DADL and [~H]naloxone binding were each examined by two methods. Initially, [3H]DADI. binding was performed in 50 mM Tris-HCl (pH 7.4), 3(./ mM NaCI, 3 mM manganese acetate and 2 j~M GTP: pH]naloxone binding was carried out in 50 mM Tris-HCl (pH 7.4) and 100 mM NaCI. Subsequent studies were carried out in 150 mM Tris-HCl (pH 7.4) and cither PHIDADL plus 500 nM morphiceptin (to block [~H]DADL binding to mu receptors) or pH]naloxone plus iII nM delta receptor peptide (to block [~H]naloxone hinding to delta receptors). At one and eight weeks in the lesioned striatum, [~H]DADL binding was reduced by 70c,;-and 82c>;, respectively, when compared to the control side.
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[~H]Naloxone binding was reduced by 35~4 and 20(; -. In GP and SN~, [~H]DADL binding was reduced by 31% and 41 ¢:'f, respectively, at one week and 27% and 2654 at eight weeks. I~H]Naloxone binding was reduced 19(,: in GP at eight weeks. A parsimonious explanation of these results is that opiate binding sites arc located on presynaptic terminals of striatal efferent fibers ko globus pallidus and substantia nigra pars reticulata as well as on local striatal axon collaterals. Since opiate pcptides have recently been found to coexist with GABA in some striatal neurons, opiate peptides may play a role in striatal function by controlling GABA relcase from striatal efferent fibers. It is possible that pallidal and nigral opiatc binding could be utilized as a marker for striatal tcrminals.
1NTR()DUCTION
Neurons and presynaptic terminals in the striatum contain high concentrations of enkephalin-like immunoreactivity ~2L~.ls,27,as,5~. There are also high levels of enkephalin in the lateral globus pallidus (Gp)s.9.11 13,27,as,53 and some is present in the substantia nigra pars reticulata (SNr)12.13. lmmunohistochemical studies suggest that the enkephalin in GP and SN, is located primarily in presynaptic terminals 12.as. The peptide is released from these terminals after electrical stimulation of caudate nucleus 24. After striatal lesions or deafferentation, enkephalin levels in GP and SNr fall markedly s,9,11,13,as. Taken together, this evidence suggests that there is a major enkephalinergic pathway from the striatum to the GP and a lesser pathway to SNr.
Despite this evidence for an enkephalinergic striatopallidal and striatonigral pathway in rat, only low levels of both mu and delta opiate receptors have been found in the GP and SNr~,~'.w->,al,51. In contrast, high levels of mu and delta opiate receptors have been observed in striatum ~,~.r,2~,22,41.51 . Some striatal opiate receptors appear to be localized on the axon terminals of dopaminergic and serotonergic striatal afferent fibers>,39 and may function to control dopamine and serotonin release. However, the role of opiates and opiate receptors in striatal function and output is largely unknown. We have measured opiate receptors in the striatum and the primary striatal projection areas after destruction of striatal neurons with kanic acid.
